期刊名称：MEDICAL ONCOLOGY
 期刊简介(About the journal)
投稿须知(Instructions to Authors)
编辑部信息(Editorial Board)
About the journal
Medical Oncology
|
Medical Oncology is a well-established, highly reputed international peer-reviewed journal featuring original papers and reviews dedicated to the study of those areas of oncology and hematology that are most relevant to clinical practice. The focus of the journal includes not only the biology, immunology, epidemiology, pathology, pathogenesis and genetics of malignant tumors, but also the widest coverage of clinical issues associated with the disease. Topics |
 |
treated run the gamut from articles on the diagnosis, treatment and prevention of solid and hematologic tumors, to work on the psychological, social and economic aspects of cancer. The journal also features review articles on the practice of medical oncology, and brief case reports highlighting elements of clinical practice.
Medical Oncology communicates the results of clinical and experimental research in oncology and hematology, particularly with experimental therapeutics with the field of immunotherapy and chemotherapy. It also provides state-of-the-art reviews on clinical and experimental therapies in oncology and hematology. Topics covered include immunobiology, pathogenesis, and treatment of malignant tumors.
Abstracted/Indexed in:
Cambridge Scientific Abstracts
Current Contents/Clinical Medicine
Research Alert
Science Citation Index
Index Medicus/MEDLINE
PUBMED
Excerpta Medica/EMBASE
Biological Abstracts/BIOSIS
AIDS & Cancer Research
Instructions to Authors
Submission
- Submit manuscripts prepared as outlined below to one of the Editors
- Four complete copies of each manuscript, including figures and tables, should be submitted directly to the editorial office in your region
- The original manuscript and one set of high-quality figures should be marked as such
- Please enclose a covering letter including the corresponding author's complete address, e-mail address, telephone number, and fax number
- To expedite the review process, authors may recommend three to five reviewers
- Please provide the name, address, e-mail address, telephone and fax numbers, and area of expertise. Note that the recommended reviewers will be used at the discretion of the Editor
- Acknowledgment of receipt of the manuscript by the editorial office will be sent to the corresponding author, including an assigned manuscript number, which should be included in all subsequent correspondence
- When sending in a revised manuscript, this should be clearly marked as such and should include the manuscript number
Scope
Medical Oncology (MO) communicates the results of clinical and experimental research in oncology and hematology, particularly with experimental therapeutics with the field of immunotherapy and chemotherapy. It also provides state-of-the-art Reviews on clinical and experimental therapies in oncology and hematology. Topics covered include immunobiology, pathogenesis, and treatment of malignant tumors.
Reviews
- Scholarly reviews of topics within the scope of MO will be considered for publication after peer-review
- Please send a one-page letter of inquiry to an Editor before preparing your manuscript, to make sure that a similar review is not in preparation
Manuscripts
- Type manuscripts in English, double-spaced on one side of consecutively numbered pages, with 1- to 1.5-in. margins
- Please subdivide the manuscript into the following sequence of sections: Title page, Abstract, Key Words (for indexing purposes), Introduction, Materials and methods, Results, Discussion, Acknowledgment, References, Tables, Figure legends. Full-length papers of over 45 pages (including tables and figures) are discouraged
- Papers not following the indicated format may be returned
Submission on Disk
- Once accepted for publication, the final version of the manuscript must be submitted on disk
- The preferred electronic version of your manuscript is Microsoft Word, in Macintosh format
- PC-prepared disks are also acceptable. Manuscripts and electronic versions must match
- Revised electronic versions cannot be submitted without a corresponding reprinted manuscript
Copyright Transfer Agreement
- Please include; manuscripts cannot be published without author's signed and dated form
Abstracts
- The second page of the manuscript should contain only an abstract in a single paragraph of not more than 250 words
- Abbreviations and reference citations should not be used
Index Entries
- The title should be as brief as possible with no abbreviations
- Include each author's surname and initials and complete addresses in English, including department, institution, city with postal code, and country (indicating clearly which author is at which address)
- A corresponding author should be indicated, with telephone and fax numbers and e-mail address provided
- Please also provide a running title of not more than 50 characters, and 5 to 10 keywords using standard MeSH-Medline subject headings for indexing purposes, Terms not contained within the title are preferred
Introduction
- The introduction should assume that the reader is knowledgeable in the field and should therefore be as brief as possible and never to exceed 1500 words
References
- References should follow the Vancouver format
- In the text, they should appear as numbers starting at 1
- At the end of the paper they should be listed (double-spaced) in numerical order corresponding to the order of citation in the text
- All authors should be quoted for papers with up to five authors; for papers with more that five authors, the first author only should be quoted followed by et al
- Abbreviations for titles of medical periodicals should conform to those used in the latest edition of Index Medicus/Medline
- The first and last page numbers for each reference should be provided
Abstracts and letters must be identified as such:
1 Clements R, Gravell IH. Radiological appearances of hydatid disease in Wales. Postgrad Med J 1986; 62:167–173.
2 Greenberger JS, Long-term hematopoietic cultures. In: Golde W (ed). Hematopoiesis. Churchill Livingstone: New York, 1984, pp 203–242.
Illustrations
- All illustrations, including chemical structures, must be provided in professional-quality, finished form ready for direct reproduction without revision by us
- Electronic version in Tiff or EPS format is acceptable, with an accompanying hard copy
- Color art cannot be accepted unless the author is willing to assume the additional costs involved in production; quotes will be given on request
Tables
- Tables should be typed on separate sheets and numbered consecutively with Arabic numbers
- Tables should be self-explanatory and include a brief descriptive title
- Footnotes to tables indicated by lower case letters are acceptable, but they should not contain extensive experimental detail
Abbreviations
- Abbreviations should be defined after their first mention in the text, except for the use of accepted abbreviations, such as SI symbols, which need not be defined
- Use generic names when referring to drugs; trade names may be given in parentheses at first mention
Page charges
- There are NO page charges for accepted articles
Reprints
- Reprints are available to authors at standard rates
Editorial Board
Editors
Peter H. Wiernik, MD
Director, Comprehensive Cancer Center
Our Lady of Mercy Medical Center
New York Medical College,
600 East 233rd Street
Bronx, NY 10466
PH: (718) 920-1113
FX: (718) 920-1123
E-mail: pwiernik@aol.com
Janice P Dutcher, MD, Associate Editor (Comprehensive Cancer Center, Our Lady of Mercy Medical Center, New York Medical College, Bronx, NY)
Thomas Miale, MD, Associate Editor (Dept of Pediatrics, University of Tennesse Medical Center, Knoxville, TN)
Giuseppe Masucci, MD, Associate Editor (Dept of Oncology, Radiumhemmet, Stockholm, SWEDEN)
Joseph Aisner, MD, Associate Editor (Cancer Institute of New Jersey, New Brunswick, NJ)
|
Associate Editors
Janice P Dutcher, Bronx, NY
Thomas Miale, Knoxville, TN
Giuseppe Masucci, Stockholm, SWEDEN
Joseph Aisner, New Brunswick, NJ
Founding Editors:
J. F. Holland, MD, New York, NY
G. Mathé, MD, Villejuif, FRANCE
Editorial Board:
K. C. Anderson, Boston, MA
J. F. Bishop, Camperdown, AUSTRALIA
G. Bonadonna, Milan, ITALY
F. Caligaris-Cappio, Torino, ITALY
D. Catovsky, London, UK
M. Cazzola, Pavia, Italy
M. Colovic, Belgrade, YUGOSLAVIA
A. Forastiere, Baltimore, MD
H. Hansen, Copenhagen, DENMARK
R. Hast, Stockholm, SWEDEN
E. M. Ibrahim, Riyadh, SAUDI ARABIA
H. E. Johnsen, Herlev, DENMARK
L. Kvols, Tampa, FL
H. Mellstedt, Stockholm, SWEDEN
B. Modan, Tel-Hashomer, ISRAEL
A. Nagler, Jerusalem, ISRAEL
M. R. Nowrousian, Essen, GERMANY
D. Petrylak, New York, NY
K. R. Rai, New Hyde Park, NY
U. Ringborg, Stockholm, SWEDEN
L. Rodriguez-Rodriguez, New Brunswick, NJ
J. Ruckdeschel, Tampa, FL
J. F. San Miguel, Salamanca, SPAIN
E. Vellenga, Gronigen, THE NETHERLANDS
A. Waage, Trondheim, NORWAY
J. Walewski, Warsaw, POLAND
R. Weiner, New Orleans, LA
J. Wong, SINGAPORE
H. Zwierzina, Innsbruck, AUSTRIA |
Anders Osterborg, MD, PhD
Department of Oncology (Radiumhemmet)
Karolinska Hospital
SE-17176 Stockholm
SWEDEN
PH: +46 8 517 733 85
FX: +46 8 318327
E-mail: anders.osterborg@ks.se
|
刊名字顺( Alphabetical List of Journals):
返回页首 